Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gastric Balloon Labeling Updated After Patient Deaths

Executive Summary

US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.

You may also be interested in...



FDA Updates On Hyperinflation, Pancreatitis Risks Of Implantable Liquid-Filled Weight-Loss Balloons

A letter from the US agency clarifies the risks of over-inflation, acute pancreatitis and death in patients who have been treated with liquid-filled intragastric balloons.

Apollo And ReShape Swap Bariatric Devices

Apollo Endosurgery sold its surgical product line, including the Lap-Band adjustable gastric banding system and other accessories for laparoscopic bariatric surgery, to ReShape Lifesciences for $17m plus other considerations, including the ReShape endoscopic balloon, the companies announced Dec. 18. The deal will allow Apollo to focus on endo-bariatric procedures while it gives ReShape an instant revenue stream and another product to sell to surgeons, its core customers.

Gastric Balloon-Makers Respond To US FDA Warning

Apollo Endosurgery and Reshape Medical are both defending their products’ safety in the wake of a US FDA letter warning of five deaths tied to the companies' intragastric balloon devices.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel